Infectious Diseases
Palau Pharma S.L. is involved in clinical research focused on fungal infections, with activity centred on acute vulvovaginal candidiasis and acute Candida vulvovaginitis. Its trial portfolio reflects interest in therapies for symptomatic candidal infection affecting the female genital tract.
- Vulvovaginal candidiasis
- Candida vulvovaginitis
- Antifungal treatment
The sponsor’s research activity is concentrated on clinical options for managing localized yeast infection and related gynecological infectious disease.
Women’s Health
The sponsored research addresses conditions within gynaecology, particularly infections that cause discomfort, discharge, and irritation in women. The therapeutic focus lies in treatment areas relevant to reproductive tract health and intimate care.
- Gynaecological infection
- Female reproductive health
- Genital tract symptoms
Clinical interest in this area supports evaluation of therapies intended for symptomatic relief and infection clearance in women.
Antifungal Therapeutics
Palau Pharma S.L. explores antifungal drug development through research on albaconazole in comparison with established treatment and placebo. The therapeutic domain includes agents aimed at treating yeast-associated mucosal infection.
- Azole antifungals
- Albaconazole
- Comparative antifungal therapy
This area of interest is aligned with the development of medicines for localized mycotic disease in outpatient settings.
Clinical Pharmacology
The trial activity includes assessment of efficacy, safety, and pharmacokinetics for an oral antifungal candidate. This places emphasis on the clinical behaviour of treatment options used for uncomplicated fungal infection.
- Drug efficacy
- Safety evaluation
- Pharmacokinetic profiling
Research in this domain supports understanding of how antifungal agents perform in human infection management.
